麻豆传媒

Meeting Coverage >

ACC

Wegovy Helps HFpEF Patients With Diabetes Mellitus

Weight and symptoms improved in STEP-HFpEF DM trial

Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor

Yet empagliflozin gets a boost from a lower risk of total HF events in EMPACT-MI

Cardiology's Bid to Defect From ABIM Plows Ahead

Application to form a new board is in, and it could be operational as soon as 2025

Interatrial Shunt's Prospects in Heart Failure Shrink After RELIEVE-HF

Ventura device showed promise in narrower pool of HF patients with reduced EF

ACC Meeting to Make Noise on Beta-Blockers, SGLT2i, Chelation Therapy for Acute MI

Plus an update on the new cardiovascular board at Atlanta meeting

More Sophisticated Imaging Doesn't Necessarily Mean Better Outcomes in Ischemic HF

But cardiac MRI, PET may still have value in some patients, per AIMI-HF trial

Adaptive Pacemaker Fails in HFpEF

Improvement in oxygen consumption response to physical exertion not observed in a small trial

Pulsed Field Afib Ablation Hits Endpoints in Pivotal Trial

Technology appears durable in most patients

Virtual Care Team Optimized Heart Failure Medications During Hospitalization

Trial shows modest effect with daily recommendations to the treating team

Statin Users Show LDL Doesn't Come Close to Telling Whole Story of ASCVD

Residual inflammation is important factor of cardiovascular risk

Elite Athletes With Genetic Heart Disease Can Still Play Ball

With a comprehensive return-to-play protocol, most athletes played again, researchers say

Full-Dose Anticoagulation Again Favored for COVID Admissions

Despite failures, FREEDOM trial supports mortality advantage in general ward use

Sotatercept, Fixed-Dose Combo Therapy on the Right Path for PAH

More therapeutic options suggested by STELLAR, A DUE trials

Thrombectomy Linked to Better High-Risk Pulmonary Embolism Outcomes

Observational study suggests fewer deaths than with other approaches

TAVR Holds Strong 3 Years Into Evolut Low Risk Trial

No major widening nor narrowing of event curves yet

No Copay Is No Help for CVD Outcomes

Randomized trial showed a small bump in adherence, but didn't move the dial on outcomes

Minimally Invasive Mitral Valve Surgery Earns Confidence in Expert Hands

Decision for mini thoracotomy may rest on patient preference, expert operator availability

Immediate Complete Revascularization Non-Inferior to Staged Procedure

Patients with ACS and multivessel disease saw multiple outcome benefits in BIOVASC trial

Hunt for Hibernating Myocardium Doesn't Help PCI for Ischemic Cardiomyopathy

REVIVED-BCIS2 challenges long-held beliefs about myocardial viability

Novel Antihypertensive Stumbles Over Early-Phase Hurdle

Hopes remain high for baxdrostat despite trial's adherence problems

TEER Improves Quality of Life With Severe Tricuspid Regurgitation

Pivotal trial is first to evaluate "impact of TR reduction on long-term effects on survival"

Bempedoic Acid Proves Clinical Benefits for the Statin-Intolerant

Yet the good clinical data are complicated by real-world cost and access problems

Atorvastatin Tied to Cardioprotection for Lymphoma Patients on Anthracyclines

STOP-CA deemed "an impactful study that will lead to more prescription of statins in patients."

Gender Affirmation Hormones Come With Cardiovascular Tradeoffs

National hospital data add to the literature on HRT's risk-benefit profile

Anticoagulation Goes Head-to-Head With DAPT After Valve Surgery

Edoxaban not significantly better for thrombosis protection in "underpowered" ADAPT-TAVR trial

Two PCI Guidance Strategies on Par for Intermediate Coronary Stenosis

FLAVOUR trial weighs in on FFR versus IVUS

Which Drug-Coated Balloon Proved Superior in Peripheral Artery Disease?

Second-generation device goes head-to-head with popular first-gen device

Cardiac Monitoring Finds Arrhythmias, but Treatment Did Not Improve Outcomes

No differences in mortality, hospitalization between monitored patients and control patients

TAVR Valve Outlasts Surgical Bioprostheses at 5 Years

No longer assume that TAVR bioprostheses are inherently less durable

Study Provides 'Elusive' Link Between Kids' Health and Adult Heart Events

CV risk factors in childhood tied to midlife CV events and CVD

Patiromer Limits Impact of RAAS Inhibitor-Related Hyperkalemia in HF

Patients better able to achieve target dose of mineralocorticoids and angiotensin inhibitors

Transcatheter Tricuspid Repair Shows Early Promise

PASCAL device safe and linked to symptom improvement in severe tricuspid regurgitation

Extra Warming Efforts in Surgery Turn Out to Be Hot Air

PROTECT trial finds targeting body temperatures a few degrees higher is unnecessary

Flu Vaccine Didn't Stop Vascular Events in Heart Failure Patients

But study in lower income countries sees hint of benefit during peak disease season

Shoppers Adhered to Heart-Healthy Diet in Novel Program

Researchers teamed with supermarket chain to improve DASH scores

Don't Wait, Ablate to Prevent VT Episodes After an ICD Shock?

Early catheter ablation reduced deaths and ICD shocks in PARTITA trial

EHR Pop-Ups Spur Better GDMT Implementation in Heart Failure

Alert-based intervention in PROMPT-HF trial said to be low-cost, scalable

Higher-Dose ANGPTL3 Inhibitor Cuts Lipids but With Questionable Safety

Significant safety signals in dose-ranging trial may end drug's future in CV prevention

Add-On Mavacamten Cuts Need for Septal Reduction in Obstructive HCM

VALOR-HCM trial shows novel cardiac myosin inhibitor beneficial as targeted treatment

Tide Turns on Withholding Blood Pressure Meds for Pregnant Women

Antihypertensive treatment was safe for mothers and children in the CHAP trial

1